

LIST OF FIGURES

Part I : Potential NMDA Receptor Antagonist		Page No
Fig. 1.1	Progressive illustrations of brain degeneration caused by Alzheimer's disease.	05
Fig. 1.2	Therapeutic targets for Alzheimer's disease,	06
Fig. 1.3	Schematic illustration of apoptotic pathways triggered by excessive NMDA receptor activity.	14
Fig. 1.4	NMDA receptor model illustrating important binding and modulatory sites.	15
Fig. 3.1	Development of 3-benzazepines as NMDA receptor antagonists.	32
Fig. 3.2	SAR of benzazepines for NMDA receptor glycine site antagonistic activity	33
Fig. 3.3	Designed benzazepine-2-ones with substituents at 1 and 3 position	33
Fig. 4.1	<i>In vitro</i> neuroprotective potential of the test compounds (9 and 14) against A β ₁₋₄₂ -induced toxicity.	67
Fig. 4.2	Morris water maze test	68
Fig. 4.3	<i>in vitro</i> ROS scavenging and antiapoptotic effects	69
Part II : Novel Cholinesterase Inhibitors		Page No
Fig. 1.1	Changes in Alzheimer's brain	02
Fig. 1.2	FDA approved anticholinesterase drugs for Alzheimer's disease	03
Fig. 3.1	2,3-Substituted Quinazolinones as CNS acting agents	24
Fig. 3.2	Compounds with good anticholinesterase activity	25
Fig. 4.1	Test compound (75) enhanced spatial learning ability of scopolamine-induced amnesic mice in MWM test.	46
Fig. 4.2	Test compound (75) restored immediate working memory impairment induced by ICV injection of A β ₁₋₄₂ in hippocampal region of rat brains as observed in Y maze test.	47
Fig. 4.3	<i>In vitro</i> ROS scavenging and antiapoptotic effects of test compound (75) against A β ₁₋₄₂ -induced toxicity of hippocampal neurons.	48